A Phase I, Open-Label, First-Time-In-Human Study of the Oral AKT Inhibitor GSK2141795

NCT00920257 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

77

Enrollment

INDUSTRY

Sponsor class

Conditions

Cancer

Interventions

DRUG: GSK2141795

Sponsor

GlaxoSmithKline